About Doptelet®

About DOPTELET

In 2 randomized, double-blind, placebo-controlled studies (N=435):

  • DOPTELET significantly reduced the need for platelet transfusion or any rescue procedure for bleeding 7 days after a procedure compared to placebo1*

  • On average, patients taking DOPTELET nearly doubled their platelet count in time for a procedure1

  • Significantly more patients taking DOPTELET reached a platelet count ≥50,000/μL compared to placebo1†

  • DOPTELET had a safety profile similar to placebo

  • DOPTELET has 2 dosing options based on your patient’s baseline platelet count1

DOPTELET works with the body to increase platelet counts1

DOPTELET provides added protection during and after the procedure1

DOPTELET provides added protection during and after the procedure

 

*From randomization of DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days up to 7 days after a procedure, compared to placebo (P<.001; N=435).1

On procedure day, 10 to 13 days after starting DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days, compared to placebo (P<.0001; N=435).1

In pooled analysis of ADAPT-1 and ADAPT-2 (N=251).2

DOPTELET is an oral treatment that helps patients produce more of their
own platelets1

View the DOPTELET Mechanism of Action

 

 

References:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2018.

2. Data on file. Dova Pharmaceuticals, Inc.